このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cocrystal Pharma マネジメント

マネジメント基準チェック /34

Cocrystal Pharma'sの CEO はSam Leeで、 Jan2008年に任命され、の在任期間は 16.42年です。の年間総報酬は$ 627.20Kで、 62.9%給与と37.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.36%を直接所有しており、その価値は$ 90.52K 。経営陣と取締役会の平均在任期間はそれぞれ16.4年と4.7年です。

主要情報

Sam Lee

最高経営責任者

US$627.2k

報酬総額

CEO給与比率	62.9%
CEO在任期間	16.5yrs
CEOの所有権	0.4%
経営陣の平均在職期間	16.5yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

CEO報酬分析

Cocrystal Pharma の収益と比較して、Sam Lee の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$627k	US$395k	-US$18m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$622k	US$371k	-US$39m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$665k	US$333k	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$462k	US$293k	-US$10m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$241k	US$241k	-US$48m
Sep 30 2019	n/a	n/a	-US$45m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$45m
Dec 31 2018	US$412k	US$201k	-US$49m
Sep 30 2018	n/a	n/a	US$435k
Jun 30 2018	n/a	n/a	US$41k
Mar 31 2018	n/a	n/a	US$382k
Dec 31 2017	US$253k	US$253k	-US$613k

報酬と市場: Samの総報酬 ($USD 627.20K ) は、 US市場 ($USD 678.50K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Samの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Sam Lee (64 yo)

16.5yrs

在職期間

US$627,201

報酬

Dr. Sam Lee, Ph D., Co-founded Cocrystal Pharma, Inc. in 2008 and serves as its President since January 2, 2014 and serves as its Interim Co-Chief Executive Officer since May 2023 and had been its Interim...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Roger Kornberg	Co-Founder	4.3yrs	US$184.84k	0.39% $ 92.7k
Sam Lee	Co-Founder	16.5yrs	US$627.20k	0.36% $ 84.7k
James Martin	Co-CEO, CFO & Corporate Secretary	7.1yrs	US$627.20k	0.0056% $ 1.3k

16.5yrs

平均在職期間

64yo

平均年齢

経験豊富な経営陣: COCPの経営陣は経験豊富で経験豊富です（平均在職期間は16.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Roger Kornberg	Co-Founder	4.3yrs	US$184.84k	0.39% $ 92.7k
Fred Hassan	Independent Director	1.3yrs	US$49.47k	9.98% $ 2.4m
Richard Pfenniger	Independent Director	3.2yrs	US$44.23k	0.033% $ 7.8k
Phillip Frost	Independent Director	10.5yrs	US$84.12k	13.1% $ 3.1m
Steven Rubin	Independent Vice Chairman	10.5yrs	US$113.51k	0.019% $ 4.6k
Michael Levitt	Member of Scientific Advisory Board	no data	データなし	データなし
Gary Schoolnik	Member of Scientific Advisory Board	no data	データなし	データなし
Bob Lehman	Member of Scientific Advisory Board	no data	データなし	データなし
Roland Strong	Member of Scientific Advisory Board	no data	データなし	データなし
Christophe Verlinde	Member of Scientific Advisory Board	no data	データなし	データなし
Anthony Japour	Independent Director	5.3yrs	US$79.97k	0% $ 0
Baek Kim	Member of Scientific Advisory Board	no data	データなし	データなし

4.8yrs

平均在職期間

77yo

平均年齢

経験豊富なボード: COCPの取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

Cocrystal Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

Board Member recently sold US$1.7m worth of stock

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Recent updates

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program

United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc

New 90-day low - US$0.93

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $15.000001 million.

New 90-day high - US$2.36

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Value Index

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /34